Cadefrecitinib clinical trials
Also written GLPG3667.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses cadefrecitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Studies
Open first, then newest update. How each study uses cadefrecitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusCompletedPhase 2Lakefront Biotherapeutics NVNCT05856448Written as GLPG3667
- A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisCompletedPhase 2Lakefront Biotherapeutics NVNCT05695950Written as GLPG3667
- A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667CompletedPhase 1Galapagos NVNCT04097938Written as GLPG3667 oral suspension
- Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy SubjectsCompletedPhase 1Galapagos NVNCT05272683Written as GLPG3667
- Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667CompletedPhase 1Lakefront Biotherapeutics NVNCT05335447Written as GLPG3667 capsule
- A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult SubjectsCompletedPhase 1Galapagos NVNCT04976270Written as GLPG3667
- A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque PsoriasisCompletedPhase 1Galapagos NVNCT04594928Written as GLPG3667
- Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy SubjectsCompletedPhase 1Galapagos NVNCT04736927Written as GLPG3667
Codes
What other systems call cadefrecitinib · ClinicalTrials.gg INT017390
- UNII (FDA) NKX4HH6CWKCADEFRECITINIBConfirmed FDA, Wikidata
- Wikidata Q140528729cadefrecitinibConfirmed FDA, Wikidata
- NCI Thesaurus C224721CadefrecitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NKX4HH6CWK | CADEFRECITINIB | Confirmed FDA, Wikidata |
| Wikidata | Q140528729 | cadefrecitinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C224721 | Cadefrecitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.